载脂蛋白H在儿童脓毒症中的保护作用
该研究检测儿童脓毒症患者与健康人APOH浓度,并在盲肠结扎穿刺(CLP)小鼠脓毒症模型中观察APOH对生存、器官损伤和炎症的影响,同时在多种巨噬细胞中探讨抗炎机制。试点队列中脓毒症患者APOH相对丰度(2.94 ± 0.61)高于健康对照(1.13 ± 0.84)(p < 0.001),非存活者(0.50 ± 0.37)低于存活者(1.45 ± 0.83)(p < 0.05);验证队列中脓毒症患者血清APOH浓度(202.0 ± 22.5 ng/ml)低于健康对照(409.5 ± 182.9 ng/ml)(p < 0.0001)。小鼠中给予重组APOH蛋白降低严重脓毒症死亡率、减轻器官损伤并抑制炎症;用抗APOH单克隆抗体中和APOH则增加非严重脓毒症小鼠死亡率、加重器官损伤和炎症。机制上APOH通过抑制TLR4/NF-κB信号通路抑制巨噬细胞M1极化。
要点
- 验证队列中儿童脓毒症患者血清APOH浓度(202.0 ± 22.5 ng/ml)低于健康对照(409.5 ± 182.9 ng/ml)(p < 0.0001)。
- 试点队列中脓毒症非存活者APOH水平(0.50 ± 0.37)低于存活者(1.45 ± 0.83)(p < 0.05)。
- 小鼠严重脓毒症中给予重组APOH蛋白可降低死亡率、减轻器官损伤并抑制炎症。
- 小鼠非严重脓毒症中用抗APOH单克隆抗体中和APOH可增加死亡率、加重器官损伤和炎症。
- APOH对细菌负荷、中性粒细胞和巨噬细胞计数影响很小,对铜绿假单胞菌感染中PMs、RAW 264.7细胞和PBMCs的细菌吞噬和杀伤影响可忽略。
适用人群与场景
- 儿童脓毒症患者(试点队列与验证队列)及健康对照。
- 盲肠结扎穿刺(CLP)诱导的严重脓毒症与非严重脓毒症小鼠模型。
研究设计与关键结果
- 研究类型:概念验证研究,包含儿童脓毒症患者队列检测与CLP小鼠脓毒症实验。
- 试点队列:脓毒症患者APOH相对丰度(2.94 ± 0.61)高于健康对照(1.13 ± 0.84)(p < 0.001);非存活者APOH水平(0.50 ± 0.37)低于存活者(1.45 ± 0.83)(p < 0.05)。
- 验证队列:脓毒症患者血清APOH浓度(202.0 ± 22.5 ng/ml)低于健康对照(409.5 ± 182.9 ng/ml)(p < 0.0001)。
- 小鼠严重脓毒症中给予重组APOH蛋白降低死亡率、减轻器官损伤并抑制炎症。
- 小鼠非严重脓毒症中用抗APOH单克隆抗体中和APOH增加死亡率、加重器官损伤并加剧炎症。
- APOH对脓毒症小鼠模型细菌负荷、中性粒细胞和巨噬细胞计数影响很小,对铜绿假单胞菌感染中PMs、RAW 264.7细胞和PBMCs的细菌吞噬和杀伤影响可忽略。
- 机制:在PMs和RAW 264.7细胞中,APOH通过抑制TLR4/NF-κB信号通路抑制巨噬细胞M1极化。
证据类型、等级与局限
- 证据类型:概念验证研究(包含临床队列观察与动物实验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为APOH在宿主对脓毒症的防御反应中具有保护作用,突显APOH在脓毒症治疗中的潜在治疗价值。
- 原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis is a severe condition characterized by acute organ dysfunction resulting from an imbalanced host immune response to infections. Apolipoprotein H (APOH) is a critical plasma protein that plays a crucial role in regulating various biological processes. However, the precise role of APOH in the immunopathology of paediatric sepsis remains unclear.
METHODS: In this study, we evaluated the concentration of APOH in paediatric patients with sepsis and healthy individuals. In an experimental sepsis model of caecal ligation and puncture (CLP), the impact of APOH on survival, organ injury, and inflammation was measured. Furthermore, the anti-inflammatory effects of APOH were investigated across diverse immune cell types, encompassing peripheral blood mononuclear cells (PBMCs), peritoneal macrophages (PMs), bone marrow-derived macrophages (BMDMs), and RAW 264.7 macrophages.
RESULTS: In the pilot cohort, the relative abundance of APOH was found to be decreased in patients with sepsis (2.94 ± 0.61) compared to healthy controls (1.13 ± 0.84) (p < 0.001), non-survivors had lower levels of APOH (0.50 ± 0.37) compared to survivors (1.45 ± 0.83) (p < 0.05). In the validation cohort, the serum concentration of APOH was significantly decreased in patients with sepsis (202.0 ± 22.5 ng/ml) compared to healthy controls (409.5 ± 182.9 ng/ml) (p < 0.0001). The application of recombinant APOH protein as a therapeutic intervention significantly lowered the mortality rate, mitigated organ injury, and suppressed inflammation in mice with severe sepsis. In contrast, neutralizing APOH with an anti-APOH monoclonal antibody increased the mortality rate, exacerbated organ injury, and intensified inflammation in mice with non-severe sepsis. Intriguingly, APOH exhibited minimal effects on the bacterial burden, neutrophil, and macrophage counts in the sepsis mouse model, along with negligible effects on bacterial phagocytosis and killing during Pseudomonas aeruginosa infection in PMs, RAW 264.7 cells, and PBMCs. Mechanistic investigations in PMs and RAW 264.7 cells revealed that APOH inhibited M1 polarization in macrophages by suppressing toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) signalling pathway.
CONCLUSION: This proof-of-concept study demonstrated that APOH has a protective role in the host defense response to sepsis, highlighting the potential therapeutic value of APOH in sepsis treatment.
参考来源
- Yu Z, Xiao C, Liu R, et al. The protective effect of apolipoprotein H in paediatric sepsis. Crit Care. 2024. PMID: 38291524. doi:10.1186/s13054-024-04809-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。